EXHIBIT 10.20
*** TEXT OMITTED AND FILED SEPARATELY
PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST
UNDER 17 C.F.R. SECTION 200.80(b)(4)
AND RULE 406 UNDER THE SECURITIES
ACT OF 1933, AS AMENDED
AMENDMENT TO AGREEMENT
THIS AMENDMENT TO AGREEMENT (the "Amendment") is made and entered into
effective as of November 11, 2004 (the "Amendment Effective Date"), by and
between STRUCTURAL GENOMIX, INC., a corporation organized and existing under the
laws of the State of Delaware and having its principal place of business located
at 00000 Xxxxxxx Xxxxxx, Xxx Xxxxx, XX 00000 ("SGX") and XXX XXXXX AND COMPANY.,
a corporation organized and existing under the laws of the state of Indiana and
having its principal place of business at Lilly Xxxxxxxxx Xxxxxx, Xxxxxxxxxxxx,
Xxxxxxx 00000, ("Lilly"). Lilly and SGX may be referred to herein as a "Party"
or, collectively, as "Parties".
RECITALS
X. Xxxxx and SGX have entered into a Collaboration and License
Agreement effective April 14, 2003, as amended July 1, 2003 and January 30, 2004
(the "Agreement"), under which the Parties have agreed to conduct a
collaborative research program.
B. The Parties desire to amend the terms of the Agreement as provided
in this Amendment.
NOW, THEREFORE, the Parties agree as follows:
1. AMENDMENT OF THE AGREEMENT
The Parties hereby agree to amend the terms of the Agreement as
provided below, effective as of the Amendment Effective Date. To the extent that
the Agreement is explicitly amended by this Amendment, the terms of the
Amendment will control where the terms of the Agreement are contrary to or
conflict with the following provisions. Where the Agreement is not explicitly
amended, the terms of the Agreement will remain in force. Capitalized terms used
in this Amendment that are not otherwise defined herein shall have the same
meanings as such terms are defined in the Agreement.
1.1 AMEND SECTION 4.1. Section 4.1 of the Agreement is hereby amended
to delete subsection (c) in its entirety and replace it with the following: "(c)
(i) Within forty-five (45) days after the Amendment Effective Date, Lilly will
pay SGX a non-refundable research fee of $2,500,000, provided however, that SGX
has committed a total of [...***...] ([...***...]) [...***...] to the Research
Collaboration during the period between March 26, 2003 and the Amendment
Effective Date; and (ii) within forty-five (45) days after the second
anniversary of the Effective Date, Lilly will pay SGX a non-refundable research
fee of $1,500,000, provided however, that SGX has committed a total of
[...***...] ([...***...]) [...***...] to the Research Collaboration during the
period between March 26, 2003 and the second anniversary of the Effective Date.
If SGX has not honored such [...***...] ([...***...]) [...***...] commitment,
then Lilly will pay SGX a pro-rated amount under sub-paragraph (ii) above,
proportionate with the amount of FTEs that have actually been used as long as
the total number of FTEs committed by SGX during the period between March 26,
2003 and the second anniversary of the Effective Date exceeds [...***...]."
1. ***CONFIDENTIAL TREATMENT REQUESTED
2. MISCELLANEOUS
2.1 FULL FORCE AND EFFECT. This Amendment amends the terms of the
Agreement and is deemed incorporated into, and governed by all other terms of,
the Agreement. The provisions of the Agreement, as amended by this Amendment,
remain in full force and effect.
2.2 COUNTERPARTS. This Amendment may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the Parties have executed this Amendment in
duplicate originals by their authorized officers as of the date and year first
above written.
XXX XXXXX AND COMPANY
By: /s/ [illegible]
-------------------------------------
Title: VP, DCRT
----------------------------------
STRUCTURAL GENOMIX, INC.
By: /s/ Xxxxxxx X. Xxxxxx
-------------------------------------
Title: Vice President, Finance
----------------------------------
2.
